Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 9, 2010, Pages 3966-3971

  Al Jamal, Khuloud T ^a   Al Jamal, Wafa T ^a   Akerman, Simon ^b,e   Podesta, Jennifer E ^a   Yilmazer, Açelya ^a   Turton, John A ^a,f   Bianco, Alberto ^c   Vargesson, Neil ^d,g   Kanthou, Chryso ^b   Florence, Alexander T ^a   Tozer, Gillian M ^b   Kostarelos, Kostas ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c CNRS   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Nanoparticle

Indexed keywords

CD31 ANTIGEN; DENDRIMER; DIAGNOSTIC AGENT; MATRIGEL; POLYLYSINE; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FEMALE; MICROSCOPY; MOLECULE; MOUSE; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; SAFETY; SARCOMA; SCID MOUSE; SKINFOLD; SOLID TUMOR; TAIL; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CATIONS; CELL DIVISION; DENDRIMERS; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS, EXPERIMENTAL; POLYLYSINE;

ANIMALIA; MURINAE; MUS; RATTUS;

EID: 77749233942     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908401107     Document Type: Article

References (40)

1. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med, 333:1757-1763.
2. Kerbel RS (2000) Tumour angiogenesis: Past, present and the near future. Carcinogenesis, 21:505-515.
3. Folkman J (1972) Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg, 175:409-416.
4. Folkman J (2003) Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther, 2:S127-S133.
5. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov, 6:273-286.
6. Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther, 7:3670-3684.
7. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J (1980) Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med, 152:931-944.
8. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science, 235:442-447.
9. Taylor S, Folkman J (1982) Protamine is an inhibitor of angiogenesis. Nature, 297:307-312.
10. Tomalia DA, Naylor AM, Goddard WA (1990) Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Edit, 29:138-175.
11. Knopp MV, von Tengg-Kobligk H, Choyke PL (2003) Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther, 2:419-426.
12. Roberts TP, et al. (2002) Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol, 9(Suppl 2):S511-S513.
13. Marano RJ, et al. (2005) Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther, 12:1544-1550.
14. Vincent L, et al. (2003) Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies. Int J Cancer, 105:419-429.
15. Marano RJ, et al. (2004) Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res, 79:525-535.
16. Kasai S, et al. (2002) Design and synthesis of antiangiogenic/heparin- binding arginine dendrimer mimicking the surface of endostatin. Bioorg Med Chem Lett, 12:951-954.
17. Shaunak S, et al. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol, 22:977-984.
18. Al-Jamal KT, Ruenraroengsak P, Hartell N, Florence AT (2006) An intrinsically fluorescent dendrimer as a nanoprobe of cell transport. J Drug Target, 14:405-412.
19. Walter-Yohrling J, et al. (2004) Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res, 10:2179-2189.
20. Passaniti A, et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest, 67:519-528.
21. Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Res, 10:767-776.
22. Gillies ER, Frechet JM (2002) Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. J Am Chem Soc, 124:14137-14146.
23. Okuda T, et al. (2006) PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release, 116:330-336.
24. Kaminskas LM, et al. (2009) Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm, 6:1190-1204.
25. Fox ME, et al. (2009) Synthesis and In vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. Mol Pharm, 6:1562-1572.
26. Kukowska-Latallo JF, et al. (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res, 65:5317-5324.
27. Dufes C, Uchegbu IF, Schatzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev, 57:2177-2202.
28. Lawley TJ, Kubota Y (1989) Induction of morphologic differentiation of endothelial cells in culture. J Invest Dermatol, 93:59S-61S.
29. Boyd BJ, et al. (2006) Cationic poly-L-lysine dendrimers: Pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm, 3:614-627.
30. Campbell RB, et al. (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res, 62:6831-6836.
31. Eichhom M, et al. (2004) Protamine enhances uptake of cationic liposomes in angiogenic microvessels of solid tumours. Angiogenesis, 7:133-141.
32. Sakharov DV, et al. (2001) Polylysine as a vehicle for extracellular matrix-targeted local drug delivery, providing high accumulation and long-term retention within the vascular wall. Arterioscl Throm Vasc, 21:943-948.
33. Tomalia DA, Reyna LA, Svenson S (2007) Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc T, 35:61-67.
34. Dellian M, et al. (1996) Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol, 149:59-71.
35. LeunigM, et al. (1992) Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res, 52:6553-6560.
36. Ren B, et al. (2003) The antiangiogenic and therapeutic implications of endostatin. Method Find Exp Clin, 25:215-224.
37. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350:2335-2342.
38. Dings RP, et al. (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res, 13:3395-3402.
39. Medhora M, et al. (2002) Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol, 284:H215-H224.
40. Tozer GM, et al. (2005) Intravital imaging of tumour vascular networks using multiphoton fluorescence microscopy. Adv Drug Deliver Rev, 57:135-152.